ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent insulin injections, strict diet regimens, constant blood sugar monitoring, and serious chronic health conditions associated with the disease.

ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.

Company Growth (employees)
Type
Private
HQ
San Diego, US
Founded
1999
Size (employees)
67 (est)+2%
ViaCyte was founded in 1999 and is headquartered in San Diego, US

ViaCyte Office Locations

ViaCyte has an office in San Diego
San Diego, US (HQ)
3550 General Atomics Ct
Show all (1)

ViaCyte Financials and Metrics

Summary Metrics

Founding Date

1999

Total Funding

$94.9 m

Latest funding size

$10 m

Time since last funding

9 months

Investors

ViaCyte's latest funding round in May 2017 was reported to be $10 m. In total, ViaCyte has raised $94.9 m

ViaCyte's Web-traffic and Trends

ViaCyte Online and Social Media Presence

ViaCyte Company Life and Culture

You may also be interested in